Oritavancin (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Oritavancin" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

4nih.gov

4^th place

7^th place

3doi.org

2^nd place

3integratir.com

low place

3web.archive.org

1^st place

1ucl.ac.be

5,389^th place

low place

1worldcat.org

5^th place

13^th place

1fda.gov

447^th place

625^th place

1asm.org

3,555^th place

2,152^nd place

1oxfordjournals.org

1,389^th place

547^th place

1bioworld.com

low place

1fiercebiotech.com

low place

asm.org

aac.asm.org

Belley; McKay, GA; Arhin, FF; Sarmiento, I; Beaulieu, S; Fadhil, I; Parr Jr, TR; Moeck, G (2010). “Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-resistant Enterococci to Effect Rapid Bacterial Killing”. Antimicrobial Agents and Chemotherapy. 54 (12): 5369–71. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.^{[liên kết hỏng]}

bioworld.com

Tomoko Okudaira (ngày 9 tháng 5 năm 2014). “The Daily Biopharmaceutical News Source”. BioWorld. Truy cập ngày 6 tháng 6 năm 2014.

doi.org

Domenech, Oscar; Francius, Grégory; Tulkens, Paul M.; Van Bambeke, Françoise; Dufrêne, Yves; Mingeot-Leclercq, Marie-Paule (ngày 1 tháng 9 năm 2009). “Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization” (PDF). Biochimica et Biophysica Acta. 1788 (9): 1832–1840. doi:10.1016/j.bbamem.2009.05.003. ISSN 0006-3002. PMID 19450541.
Belley; McKay, GA; Arhin, FF; Sarmiento, I; Beaulieu, S; Fadhil, I; Parr Jr, TR; Moeck, G (2010). “Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-resistant Enterococci to Effect Rapid Bacterial Killing”. Antimicrobial Agents and Chemotherapy. 54 (12): 5369–71. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.^{[liên kết hỏng]}
Zhanel; và đồng nghiệp (2012). “Oritavancin: Mechanism of Action”. Clin Infect Dis. 54: S214–S219. doi:10.1093/cid/cir920.

fda.gov

News Release (ngày 6 tháng 8 năm 2014). “FDA approves Orbactiv to treat skin infections”. FDA.

fiercebiotech.com

“Biotechs pick up slack in antibiotics development”. ngày 17 tháng 5 năm 2011.

integratir.com

media.integratir.com

2007 ICAAC Posters: E-1612 "In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens"/E -1613 "In Vitro Activity Profile of Oritavancin (ORI) Against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents"/E-1614 "In vitro Time Kill Studies of Oritavancin against Drug-resistant Isolates of Staphylococcus aureus and Enterococci"/E-1615 "Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections"/E-1616 "Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections"/E-1617 "In Vitro Activity Profile of Oritavancin (ORI) Against Resistant Staphylococcal Populations From a Recent Surveillance Initiative"/E-1620 "Pharmacokinetic Concentrations of Oritavancin Kill Stationary-Phase and Biofilm Staphylococcus aureus In Vitro." / Targanta Press Release ngày 19 tháng 9 năm 2007 Lưu trữ 2011-07-13 tại Wayback Machine
ICAAC 2007 Posters: "In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin" and "Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic Clostridium difficile Spores" / Targanta Press Release ngày 19 tháng 9 năm 2007 Lưu trữ 2011-07-13 tại Wayback Machine
ASM 2007 Poster: "Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax" / Targanta Press Release ngày 24 tháng 5 năm 2007 Lưu trữ 2011-07-13 tại Wayback Machine

nih.gov

pubmed.ncbi.nlm.nih.gov

Domenech, Oscar; Francius, Grégory; Tulkens, Paul M.; Van Bambeke, Françoise; Dufrêne, Yves; Mingeot-Leclercq, Marie-Paule (ngày 1 tháng 9 năm 2009). “Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization” (PDF). Biochimica et Biophysica Acta. 1788 (9): 1832–1840. doi:10.1016/j.bbamem.2009.05.003. ISSN 0006-3002. PMID 19450541.
Scheinfeld, N (2007). “A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus”. J Drugs Dermatol. 6 (4): 97–103. PMID 17373167.
Belley; McKay, GA; Arhin, FF; Sarmiento, I; Beaulieu, S; Fadhil, I; Parr Jr, TR; Moeck, G (2010). “Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-resistant Enterococci to Effect Rapid Bacterial Killing”. Antimicrobial Agents and Chemotherapy. 54 (12): 5369–71. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.^{[liên kết hỏng]}

ncbi.nlm.nih.gov

Belley; McKay, GA; Arhin, FF; Sarmiento, I; Beaulieu, S; Fadhil, I; Parr Jr, TR; Moeck, G (2010). “Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-resistant Enterococci to Effect Rapid Bacterial Killing”. Antimicrobial Agents and Chemotherapy. 54 (12): 5369–71. doi:10.1128/AAC.00760-10. PMC 2981232. PMID 20876372.^{[liên kết hỏng]}

oxfordjournals.org

cid.oxfordjournals.org

Zhanel; và đồng nghiệp (2012). “Oritavancin: Mechanism of Action”. Clin Infect Dis. 54: S214–S219. doi:10.1093/cid/cir920.

ucl.ac.be

farm.ucl.ac.be

Domenech, Oscar; Francius, Grégory; Tulkens, Paul M.; Van Bambeke, Françoise; Dufrêne, Yves; Mingeot-Leclercq, Marie-Paule (ngày 1 tháng 9 năm 2009). “Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization” (PDF). Biochimica et Biophysica Acta. 1788 (9): 1832–1840. doi:10.1016/j.bbamem.2009.05.003. ISSN 0006-3002. PMID 19450541.

web.archive.org

2007 ICAAC Posters: E-1612 "In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens"/E -1613 "In Vitro Activity Profile of Oritavancin (ORI) Against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents"/E-1614 "In vitro Time Kill Studies of Oritavancin against Drug-resistant Isolates of Staphylococcus aureus and Enterococci"/E-1615 "Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections"/E-1616 "Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections"/E-1617 "In Vitro Activity Profile of Oritavancin (ORI) Against Resistant Staphylococcal Populations From a Recent Surveillance Initiative"/E-1620 "Pharmacokinetic Concentrations of Oritavancin Kill Stationary-Phase and Biofilm Staphylococcus aureus In Vitro." / Targanta Press Release ngày 19 tháng 9 năm 2007 Lưu trữ 2011-07-13 tại Wayback Machine
ICAAC 2007 Posters: "In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin" and "Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic Clostridium difficile Spores" / Targanta Press Release ngày 19 tháng 9 năm 2007 Lưu trữ 2011-07-13 tại Wayback Machine
ASM 2007 Poster: "Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax" / Targanta Press Release ngày 24 tháng 5 năm 2007 Lưu trữ 2011-07-13 tại Wayback Machine

worldcat.org

Domenech, Oscar; Francius, Grégory; Tulkens, Paul M.; Van Bambeke, Françoise; Dufrêne, Yves; Mingeot-Leclercq, Marie-Paule (ngày 1 tháng 9 năm 2009). “Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization” (PDF). Biochimica et Biophysica Acta. 1788 (9): 1832–1840. doi:10.1016/j.bbamem.2009.05.003. ISSN 0006-3002. PMID 19450541.